Research
Hormonal
Patients treated with semaglutide 2.4 mg had lower rates of all-cause death compared to placebo (HR: 0.81; 95% CI: 0.71-0.93).
Semaglutide may be an effective treatment for reducing overall mortality in patients with cardiovascular disease.
StrongSupportsmedium confidence
Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93).
Why this rating
Based on a large randomized controlled trial.
Source
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Benjamin M. Scirica et al. · Journal of the American College of Cardiology · 2024
DOI 10.1016/j.jacc.2024.08.007
rct · n=833Cited 43×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide treatment resulted in lower rates of non-CV death, primarily due to fewer infectious deaths (HR: 0.71; 95% CI: 0.51-0.98).Strong
- Among participants who developed COVID-19, those treated with semaglutide had fewer COVID-19-related serious adverse events and deaths (HR: 0.66; 95% CI: 0.44-0.96).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →